RBC Capital Maintains Outperform on Elevance Health, Raises Price Target to $575
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Elevance Health (NYSE:ELV) and raises the price target from $574 to $575.
April 19, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Elevance Health and raises the price target from $574 to $575.
The increase in price target by RBC Capital suggests a positive outlook on Elevance Health's stock, potentially leading to increased investor confidence and a short-term upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100